PD-1, CTLA4, and CD274 molecules are important immunotherapy targets in ccRCC, and their corresponding immune checkpoint inhibitors have been widely used in clinical treatment (Naranbhai et al., 2022; Navani and Heng, 2022). Here, CD274 is linked to nonpapillary renal cell carcinoma.